The psychopharmacology of violence with emphasis on schizophrenia, part 1: Acute treatment

Journal of Clinical Psychiatry

Volumn 68, Issue 1, 2007, Pages 163-164

  Citrome, Leslie ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; HALOPERIDOL; LORAZEPAM; OLANZAPINE; PLACEBO; RISPERIDONE; ZIPRASIDONE;

AGGRESSION; AGITATION; AKATHISIA; BIPOLAR MANIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DELUSION; DRUG ABSORPTION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HOSTILITY; HUMAN; MENTAL DISEASE; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SHORT SURVEY; SIDE EFFECT; TABLET; TARDIVE DYSKINESIA; VIOLENCE;

EID: 33846854399     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v68n0121     Document Type: Short Survey

References (21)

1. Lagos JM, Perlmutter K, Saexinger H. Fear of the mentally ill: empirical support for the common man's response. Am J Psychiatry 1977;134:1134-1136
2. Convit A, Isay D, Otis D, et al. Characteristics of repeatedly assaultive psychiatric inpatients. Hosp Community Psychiatry 1990;41:1112-1115
3. Owen C, Tarantello C, Jones M, et al. Repetitively violent patients in psychiatric units. Psychiatr Serv 1998;49:1458-1461
4. Fazel S, Grann M. The population impact of severe mental illness on violent crime. Am J Psychiatry 2006;163:1397-1403
5. Citrome L, Volavka J. Clinical management of persistent aggressive behavior in schizophrenia, pt 1: definitions, epidemiology, assessment, and acute treatment. Essential Psychopharmacology 2002;5:1-16
6. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems; 1992
7. Swanson JW. Mental disorder, substance abuse, and community violence: an epidemiological approach. In: Monahan J, Steadman HJ, eds. Violence and Mental Disorder: Developments in Risk Assessment. Chicago, Ill: University of Chicago Press; 1994: 101-136
8. Citrome L, Volavka J. Treatment of violent behavior. In: Tasman A, Kay J, Lieberman J, eds. Psychiatry, 2nd Edition. Chichester, West Sussex, England: John Wiley & Sons; 2003: 2136-2146
9. Citrome L. Atypical antipsychotics for acute agitation: new intramuscular options offer advantages. Postgrad Med 2002;112:85-88, 94-96
10. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? a multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997;15:335-340
11. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-115I
12. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled doseresponse comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-448
13. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-397
14. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002;26:494-504
15. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62:12-18
16. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001;155:128-134
17. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone IM Study Group. J Clin Psychiatry 2000;61:933-941
18. Brook S. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. J Clin Psychiatry 2003;64(suppl 19):13-18
19. Brook S, Walden J, Benattia I, et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl) 2005;178:514-523
20. Taylor D. Ziprasidone in the management of schizophrenia. The QT interval issue in context. CNS Drugs 2003;17:423-430
21. Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006;188:281-292